对CRF及其受体的结构和功能见解
Minos-Timotheos Matsoukas1, Vasilis Panagiotopoulos1, Vlasios Karageorgos2
1Department of Biomedical Engineering, School of Engineering, University of West Attica, 12243 Athens, Greece.
Biology
|February 23, 2024
概括
皮质otropin释放因子 (CRF) 和尿皮质通过CRF受体 (CRF1R和CRF2R) 调节生理功能. 这项研究详细介绍了它们的结构,激活机制和带结合,提供了治疗见解.
科学领域:
- 神经内分泌学神经内分泌学
- 分子药理学分子药理学
- 结构生物学 结构生物学
背景情况:
- 皮质激素释放因子 (CRF) 和尿皮质激素是各种生理和病理生理过程的关键调节者.
- 这些属于CRF家族,包括具有显著治疗潜力的类似物.
- 它们通过两个G蛋白结合受体发挥作用:CRF受体1型 (CRF1R) 和2型 (CRF2R).
研究的目的:
- 阐明CRF及其受体的结构特征.
- 描述CRF受体的激活机制,将其与其他G蛋白结合受体 (GPCR) 进行比较.
- 分析最近的结构数据,解释选择性带结合和受体激活.
主要方法:
- 对CRF及其相关受体的结构分析.
- 对CRF受体激活机制与其他GPCR的比较分析.
- 对有关联体受体相互作用的最新晶体学和生物化学数据的审查.
主要成果:
- 提供了CRF和CRF1R/CRF2R的详细结构描述.
- 在更广泛的GPCR超级家族中阐明了CRF受体的激活机制,并将其置于背景中.
- 介绍了对各种配体与CRF1R和CRF2R的选择性结合的结构见解.
结论:
- 了解CRF和受体的结构功能关系对于药物开发至关重要.
- 结构数据合理化了连接体选择性和受体激活,为向治疗铺平了道路.
- 这项工作为设计各种疾病的新型CRF受体调节器提供了基础.
相关概念视频
G Protein-coupled Receptors
12.0K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.0K
Transducer Mechanism: G Protein–Coupled Receptors
2.0K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.0K
GPCRs Regulate Adenylyl Cylase Activity
5.6K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Opioid Receptors: Overview
820
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
820
GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K


